Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very well produced video. Thanks!
Time for LPC to buy back those 200k commitment shares since it hit Clay’s support line at 3.14 and has traded 200k shares?
Well here it is at your $3.14. Bounce off your support line from here?
Sorry to disagree with your friend but she/he is wrong.
https://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=13642818-979-151072&type=sect&TabIndex=2&companyid=660924&ppu=%252fdefault.aspx%253fcompanyid%253d660924
Show him/her this filing. The old LPC agreement expired on Sept 6. This LPC agreement replaces it. By the way Anavex already had/has another form of financing in the form of the Cantor agreement. The Cantor agreement is a true ATM agreement whereas these LPC agreements are Equity lines of Credit. If your interested I can illustrate the difference between the two.
From these previously authorized shares.
“We are authorized to issue 100,000,000 shares of common stock with a par value of $0.001. As of August 7, 2017 we had 42,172,090 shares of common stock outstanding.”
https://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=12271363-953-95847&type=sect&TabIndex=2&companyid=660924&ppu=%252fdefault.aspx%253fcompanyid%253d660924
In a nutshell...
The old LPC agreement expired (apparently with some available shares un-issued. ) This latest filing replaces it with a new LPC agreement .
Not really a big deal from what I understand of it.
Looks like they increased the shares per day from 50k to 200k though which may have an impact on daily volume.
“The Offering
On October 21, 2015, the Company entered into the Purchase Agreement with Lincoln Park pursuant to which the Selling Security Holder agreed to purchase up to $50,000,000 shares of our common stock (subject to certain limitations) from time to time over a 36-month period to September 6, 2019.
https://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=12271363-953-95847&type=sect&TabIndex=2&companyid=660924&ppu=%252fdefault.aspx%253fcompanyid%253d660924
“On June 12, 2019, we filed a prospectus supplement to our registration statement (File No. 333-207600) (the “2016 Registration Statement”) covering the issuance and sale of (i) up to $20 million in shares of our common stock, (ii) 324,383 initial commitment shares as a commitment fee for Lincoln Park for entering into the Purchase Agreement and (iii) 64,877 additional commitment shares. As of September 11, 2019, we have sold 1,500,000 shares of common stock under the Purchase Agreement for gross proceeds of $ 4,634,505 and have issued 15,032 additional commitment shares (in addition to the 324,383 initial commitment shares), all of which were registered under the 2016 Registration Statement. As of September 6, 2019, the 2016 Registration Statement was no longer remain effective pursuant to Rule 415 under the Securities Act), so we have deregistered all remaining shares of common stock issuable under the Purchase Agreement and registered under the 2016 Registration Statement that have not been issued to Lincoln Park.
On July 3, 2019, we filed the registration statement of which this prospectus is a part, registering up to $250 million in securities utilizing a shelf registration process. Pursuant to the terms of the RRA, which requires us to register purchase shares and additional commitment shares in order to sell purchase shares to Lincoln Park, we are filing this prospectus supplement to cover (i) the offer and sale of up to $15,365,495 of shares of our common stock and (ii) the issuance of up to 49,845 additional commitment shares to be issued pro-rata to Lincoln Park if and when we direct Lincoln Park to purchase $15,365,495 of shares of common stock under the Purchase Agreement.”
I believe the old registration expired and this is its replacement.
The new expiration date is...
“Purchase of Shares Under the Purchase Agreement
From the date hereof, we may, from time to time until July 1, 2022,
https://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=13642818-979-151072&type=sect&TabIndex=2&companyid=660924&ppu=%252fdefault.aspx%253fcompanyid%253d660924
I call. Let’s wait for the flop.
I hope you win.
Ok thanks
Wow. Interesting. Thanks!
I don’t do options or short but perhaps the strategy is to be short Alzheimer’s companies when results are due but use options to protect on the upside in the rare case of a positive result. Not sure if options contracts account for increased volatility around trial results though.
House odds are on failure for sure. Sorry for patients and investors alike.
Impossible to tell the message board good guys from the bad guys until results are posted though.
Or perhaps Anavex management is smart enough to convince investors they are targeting a different MOA to attract investors?
“Researchers found that Anavex 2-73 dose-dependently prevents memory deficits and also appears to increase levels of Akt, a serine/threonine protein kinase, and decrease levels of GSK-3beta, thereby decreasing tau hyperphosphorylation.
https://www.rdmag.com/news/2011/07/anavex-2-73-amyloid-and-tau-pathology
A cursory glance makes it look worthy of further investigation.
“The Phase 2a study achieved a 100% responder rate, with all patients responding to PTI-125. A key objective of this first-in-patient study was to measure drug effects on biomarkers in the brain (i.e., in cerebrospinal fluid, or CSF) before and after 28 days of treatment with PTI-125.
Key results include:
Total tau (T-tau) decreased 20% (p<.001)
Phosphorylated tau (P-tau) decreased 34% (p<.0001)
Neurofilament light chain (NfL), a marker for neurodegeneration, decreased 22% (p<.0001)
Neurogranin, a marker for cognitive decline, decreased 32% (p<.0001)
Neuroinflammatory marker YKL-40, an indicator of microglial activation, decreased 9% (p<.0001)
Proinflammatory Interleukin 6 (IL-6) decreased 14% (p<.0001)
Proinflammatory Interleukin 1 beta (IL-1ß) decreased 11% (p<.0001)
Proinflammatory Tumor necrosis factor alpha (TNFa) decreased 5% (p=.001)
The ratio of CSF P-tau to Aß42, a widely accepted biochemical value of Alzheimer’s disease, improved in all evaluable patients (p<.001).
“We conclude from this study that PTI-125 was able to reduce biomarkers of neurodegeneration and neuroinflammation in Alzheimer’s patients at a dose that appears safe and well-tolerated,”
https://finance.yahoo.com/amphtml/news/cassava-sciences-reports-positive-phase-113000297.html
“The EXCELLENCE study is designed as an international study with the first approval by the Australian Human Research Ethics Committee and scheduled to initiate within the next quarters.”
Well, no fear of missing that self imposed deadline.
Just realized that edibles are not yet legal in Canada but that it’s close to approval. (From Stewart Varney) Should be a pretty significant bump to sales when that happens I would imagine.
What happened with the “fast track” being revealed as a footnote in a magazine article. Did the company PR it yet.
About this article
Received
28 March 2019
Revised
07 July 2019
Accepted
17 July 2019
Published
23 August 2019
Amazing how long the authors of this article have been privy to information about A2-73 that investors should have been notified of by a PR. Seriously folks...
https://www.nature.com/articles/s41392-019-0063-8#Tab2
Try this.
https://www.anavex.com/
Use the search function and search for Fast Track. Find anything? Now try “orphan”
https://www.anavex.com/?s=Orphan.
Many of these publications are fraught with mistakes. Fast track would be a big deal. I’m pretty darn sure Anavex would sing it to the heavens if they had Fast Track.
I think it might be a good idea to verify that “fast track” statement. Could it be a mistake?
“Anavex 2-73 is the second of the company’s projects to get ODD status, a designation the US Food and Drug Administration awards to fast track treatments for diseases that affect fewer than 200,000 people.”
https://www.proactiveinvestors.co.uk/companies/news/127399/anavex-life-s-alzheimer-s-drug-awarded-orphan-status-for-child-seizures-127399.html
https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
Possibly money moving to stocks unaffected by China trade. Trump’s tweet is having an effect.